Janux Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Janux Therapeutics' 2025 annual report highlights significant clinical advancements for its TRACTr and ARM platforms, alongside new and ongoing strategic collaborations.
NASDAQ
10-K: Janux Therapeutics Reports Promising Clinical Data and Outlines Growth Strategy in 10-K Filing
Janux Therapeutics' 10-K filing highlights encouraging clinical trial results for its lead candidates and details its strategic plans for future growth in the immuno-oncology space.
NASDAQ
Janux Therapeutics announces positive interim clinical data for its TRACTr platform, showing anti-tumor activity and manageable safety profiles in early trials.